Classic studies on the interaction of cocaine and the dopamine transporter

Clinical Psychopharmacology and Neuroscience

Volumn 13, Issue 3, 2015, Pages 227-238

  Verma, Vivek ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cocaine; Dopamine; Dopamine plasma membrane transport proteins; Parkinson disease; Protein protein interaction; Substance addiction

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; COCAINE; DOPAMINE TRANSPORTER; MESSENGER RNA; METIROSINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SEROTONIN TRANSPORTER; SYNUCLEIN;

ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; BINDING SITE; BLOOD BRAIN BARRIER; CHEMICAL INTERACTION; COCAINE DEPENDENCE; CONFORMATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; EXTRACELLULAR SPACE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; LOCOMOTION; MOLECULAR INTERACTION; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY DISCRIMINATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SITE DIRECTED MUTAGENESIS; SOCIAL INTERACTION; SUBSTANTIA NIGRA; SYNAPTOSOME; WITHDRAWAL SYNDROME;

EID: 84949441359     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2015.13.3.227     Document Type: Review

References (152)

1. Mohr E, Mendis T, Grimes JD. Late cognitive changes in Parkinson's disease with an emphasis on dementia. Adv Neurol 1995;65:97-113.
2. Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006;6:6.
3. Reith ME, Meisler BE, Sershen H, Lajtha A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem Pharmacol 1986;35:1123-1129.
4. Madras BK, Fahey MA, Bergman J, Canfield DR, Spealman RD. Effects of cocaine and related drugs in nonhuman primates. I. [3H]cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 1989;251:131-141.
5. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41.
6. Wang Z, Ordway GA, Woolverton W. Effects of cocaine on monoamine uptake as measured ex vivo. Neurosci Lett 2007;413:191-195.
7. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to selfadministration of cocaine. Science 1987;237:1219-1223.
8. Jones SR, Garris PA, Wightman RM. Different effects of cocaine and nomifensine on dopamine uptake in the caudate-putamen and nucleus accumbens. J Pharmacol Exp Ther 1995;274:396-403.
9. Davis M. Cocaine: excitatory effects on sensorimotor reactivity measured with acoustic startle. Psychopharmacology (Berl) 1985;86:31-36.
10. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991;14:299-302.
11. Barr GA, Rossi G. Conditioned place preference from ventral tegmental injection of morphine in neonatal rats. Brain Res Dev Brain Res 1992;66:133-136.
12. Fiorino DF, Coury A, Fibiger HC, Phillips AG. Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat. Behav Brain Res 1993;55:131-141.
13. Ikemoto S, Wise RA. Rewarding effects of the cholinergic agents carbachol and neostigmine in the posterior ventral tegmental area. J Neurosci 2002;22:9895-9904.
14. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. Limbic activation during cueinduced cocaine craving. Am J Psychiatry 1999;156:11-18.
15. Hall FS, Sora I, Drgonova J, Li XF, Goeb M, Uhl GR. Molecular mechanisms underlying the rewarding effects of cocaine. Ann N Y Acad Sci 2004;1025:47-56.
16. Hastrup H, Karlin A, Javitch JA. Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc Natl Acad Sci U S A 2001;98:10055-10060.
17. Torres GE, Carneiro A, Seamans K, Fiorentini C, Sweeney A, Yao WD, et al. Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem 2003;278:2731-2739.
18. Hastrup H, Sen N, Javitch JA. The human dopamine transporter forms a tetramer in the plasma membrane: cross-linking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs. J Biol Chem 2003;278:45045-45048.
19. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, Caron MG. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 1994;269:15985-15988.
20. Buck KJ, Amara SG. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc Natl Acad Sci U S A 1994;91:12584-12588.
21. Buck KJ, Amara SG. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol Pharmacol 1995;48:1030-1037.
22. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 2008;11:780-789.
23. Chen N, Reith ME. Structure and function of the dopamine transporter. Eur J Pharmacol 2000;405:329-339.
24. Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 1992;42:383-390.
25. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 1985;82:2173-2177.
26. Chiba K, Trevor AJ, Castagnoli N Jr. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 1985;128:1228-1232.
27. Willoughby J, Cowburn RF, Hardy JA, Glover V, Sandler M. 1-Methyl-4-phenylpyridinium uptake by human and rat striatal synaptosomes. J Neurochem 1989;52:627-631.
28. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993;61:1191-1206.
29. Storch A, Ludolph AC, Schwarz J. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 2004;111:1267-1286.
30. Di Matteo V, Benigno A, Pierucci M, Giuliano DA, Crescimanno G, Esposito E, et al. 7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study. Ann N Y Acad Sci 2006;1089:462-471.
31. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997;69:1322-1325.
32. Mayer RA, Kindt MV, Heikkila RE. Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine by inhibitors of 3, 4-dihydroxyphenylethylamine transport. J Neurochem 1986;47:1073-1079.
33. Lin Z, Itokawa M, Uhl GR. Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression. FASEB J 2000;14:715-728.
34. Dar DE, Metzger TG, Vandenbergh DJ, Uhl GR. Dopamine uptake and cocaine binding mechanisms: the involvement of charged amino acids from the transmembrane domains of the human dopamine transporter. Eur J Pharmacol 2006;538:43-47.
35. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci U S A 1992;89:7782-7785.
36. Kitayama S, Wang JB, Uhl GR. Dopamine transporter mutants selectively enhance MPP+ transport. Synapse 1993;15:58-62.
37. Pifl C, Agneter E, Drobny H, Reither H, Singer EA. Induction by low Na or Cl of cocaine sensitive carrier-mediated efflux of amines from cells transfected with the cloned human catecholamine transporters. Br J Pharmacol 1997;121:205-212.
38. Uhl GR. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Disord 2003;18 Suppl 7:S71-S80.
39. Copeland BJ, Vogelsberg V, Neff NH, Hadjiconstantinou M. Protein kinase C activators decrease dopamine uptake into striatal synaptosomes. J Pharmacol Exp Ther 1996; 277:1527-1532.
40. Huff RA, Vaughan RA, Kuhar MJ, Uhl GR. Phorbol esters increase dopamine transporter phosphorylation and decrease transport Vmax. J Neurochem 1997;68:225-232.
41. Vaughan RA, Huff RA, Uhl GR, Kuhar MJ. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem 1997;272:15541-15546.
42. Foster JD, Pananusorn B, Vaughan RA. Dopamine transporters are phosphorylated on N-terminal serines in rat striatum. J Biol Chem 2002;277:25178-25186.
43. Lin Z, Zhang PW, Zhu X, Melgari JM, Huff R, Spieldoch RL, et al. Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem 2003;278:20162-20170.
44. Corey JL, Davidson N, Lester HA, Brecha N, Quick MW. Protein kinase C modulates the activity of a cloned gamma-aminobutyric acid transporter expressed in Xenopus oocytes via regulated subcellular redistribution of the transporter. J Biol Chem 1994;269:14759-14767.
45. Qian Y, Galli A, Ramamoorthy S, Risso S, DeFelice LJ, Blakely RD. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci 1997;17:45-57.
46. Ramamoorthy S, Blakely RD. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 1999;285:763-766.
47. Melikian HE, Buckley KM. Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 1999;19:7699-7710.
48. Daniels GM, Amara SG. Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J Biol Chem 1999;274:35794-35801.
49. Doolen S, Zahniser NR. Conventional protein kinase C isoforms regulate human dopamine transporter activity in Xenopus oocytes. FEBS Lett 2002;516:187-190.
50. Torres GE. The dopamine transporter proteome. J Neurochem 2006;97 Suppl 1:3-10.
51. Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, et al. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 1999;65:PL7-PL12.
52. Rothman RB, Carroll FI, Morales M, Rowley DL, Rice KC, Dersch CM, et al. Studies of the biogenic amine transporters. 10. Characterization of a novel cocaine binding site in brain membranes prepared from dopamine transporter knockout mice. Synapse 2002;44:94-105.
53. Boja JW, Mitchell WM, Patel A, Kopajtic TA, Carroll FI, Lewin AH, et al. High-affinity binding of [125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse 1992;12:27-36.
54. Carroll FI, Abraham P, Lewin AH, Parham KA, Boja JW, Kuhar M. Isopropyl and phenyl esters of 3 beta-(4-substituted phenyl)tropan-2 beta-carboxylic acids. Potent and selective compounds for the dopamine transporter. J Med Chem 1992;35:2497-2500.
55. Rothman RB, Cadet JL, Akunne HC, Silverthorn ML, Baumann MH, Carroll FI, et al. Studies of the biogenic amine transporters. IV. Demonstration of a multiplicity of binding sites in rat caudate membranes for the cocaine analog [125I]RTI-55. J Pharmacol Exp Ther 1994;270: 296-309.
56. Staley JK, Basile M, Flynn DD, Mash DC. Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem 1994;62:549-556.
57. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 2003;479:23-40.
58. Reith ME, Coffey LL. Cationic and anionic requirements for the binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)[ 3H]tropane to the dopamine uptake carrier. J Neurochem 1993;61:167-177.
59. Chen N, Zhen J, Reith ME. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine. J Neurochem 2004;89:853-864.
60. Vaughan RA, Sakrikar DS, Parnas ML, Adkins S, Foster JD, Duval RA, et al. Localization of cocaine analog [125I]RTI 82 irreversible binding to transmembrane domain 6 of the dopamine transporter. J Biol Chem 2007;282:8915-8925.
61. Ravna AW, Sylte I, Dahl SG. Molecular model of the neural dopamine transporter. J Comput Aided Mol Des 2003;17:367-382.
62. Volz TJ, Schenk JO. A comprehensive atlas of the topography of functional groups of the dopamine transporter. Synapse 2005;58:72-94.
63. Surratt CK, Ukairo OT, Ramanujapuram S. Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters. AAPS J 2005;7:E739-E751.
64. Wang W, Sonders MS, Ukairo OT, Scott H, Kloetzel MK, Surratt CK. Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter. Mol Pharmacol 2003;64:430-439.
65. Chen N, Vaughan RA, Reith ME. The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis. J Neurochem 2001;77:1116-1127.
66. Kimmel HL, O'Connor JA, Carroll FI, Howell LL. Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol Biochem Behav 2007;86:45-54.
67. Surratt CK, Wang JB, Yuhasz S, Amzel M, Kwon HM, Handler JS, et al. Sodium-and chloride-dependent transporters in brain, kidney, and gut: lessons from complementary DNA cloning and structure-function studies. Curr Opin Nephrol Hypertens 1993;2:744-760.
68. Loland CJ, Grånäs C, Javitch JA, Gether U. Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding. J Biol Chem 2004;279:3228-3238.
69. Lin Z, Uhl GR. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol Pharmacol 2002;61: 885-891.
70. Kitayama S, Morita K, Dohi T, Wang JB, Davis SC, Uhl GR. Dissection of dopamine and cocaine binding sites on the rat dopamine transporter expressed in COS cells. Ann N Y Acad Sci 1996;801:388-393.
71. Chen JG, Sachpatzidis A, Rudnick G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J Biol Chem 1997;272:28321-28327.
72. Mitsuhata C, Kitayama S, Morita K, Vandenbergh D, Uhl GR, Dohi T. Tyrosine-533 of rat dopamine transporter: involvement in interactions with 1-methyl-4-phenylpyridinium and cocaine. Brain Res Mol Brain Res 1998;56:84-88.
73. Lin Z, Wang W, Kopajtic T, Revay RS, Uhl GR. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol Pharmacol 1999;56:434-447.
74. Lee SH, Chang MY, Lee KH, Park BS, Lee YS, Chin HR, et al. Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-3beta-(4-fluorophenyl) tropane binding of dopamine transporter. Mol Pharmacol 2000;57:883-889.
75. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, et al. Cocaine self-administration in dopaminetransporter knockout mice. Nat Neurosci 1998;1:132-137.
76. Carboni E, Spielewoy C, Vacca C, Nosten-Bertrand M, Giros B, Di Chiara G. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J Neurosci 2001;21: RC141:1-4.
77. Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, Wei HB, et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S A 2001;98:5300-5305.
78. Mateo Y, Budygin EA, John CE, Jones SR. Role of serotonin in cocaine effects in mice with reduced dopamine transporter function. Proc Natl Acad Sci U S A 2004;101:372-377.
79. Medvedev IO, Gainetdinov RR, Sotnikova TD, Bohn LM, Caron MG, Dykstra LA. Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice. Psychopharmacology (Berl) 2005;180:408-413.
80. Jones SR, Gainetdinov RR, Hu XT, Cooper DC, Wightman RM, White FJ, et al. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat Neurosci 1999;2: 649-655.
81. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379:606-612.
82. Caine SB. Cocaine abuse: hard knocks for the dopamine hypothesis? Nat Neurosci 1998;1:90-92.
83. Uhl G, Hall FS, Sora I. Cocaine, reward, movement and monoamine transporters. Mol Psychiatry 2002;7:21-26.
84. Rocha BA. Stimulant and reinforcing effects of cocaine in monoamine transporter knockout mice. Eur J Pharmacol 2003;479:107-115.
85. Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S, et al. Abolished cocaine reward in mice with a cocaineinsensitive dopamine transporter. Proc Natl Acad Sci U S A 2006;103:9333-9338.
86. Wu Q, Reith ME, Kuhar MJ, Carroll FI, Garris PA. Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission. J Neurosci 2001;21:6338-6347.
87. Greco PG, Garris PA. In vivo interaction of cocaine with the dopamine transporter as measured by voltammetry. Eur J Pharmacol 2003;479:117-125.
88. Sharpe LG, Pilotte NS, Mitchell WM, De Souza EB. Withdrawal of repeated cocaine decreases autoradiographic [3H]mazindol-labelling of dopamine transporter in rat nucleus accumbens. Eur J Pharmacol 1991;203:141-144.
89. Farfel GM, Kleven MS, Woolverton WL, Seiden LS, Perry BD. Effects of repeated injections of cocaine on catecholamine receptor binding sites, dopamine transporter binding sites and behavior in rhesus monkey. Brain Res 1992;578:235-243.
90. Byrnes JJ, Pritchard GA, Koff JM, Miller LG. Prenatal cocaine exposure: decreased sensitization to cocaine and decreased striatal dopamine transporter binding in offspring. Neuropharmacology 1993;32:721-723.
91. Pilotte NS, Sharpe LG, Kuhar MJ. Withdrawal of repeated intravenous infusions of cocaine persistently reduces binding to dopamine transporters in the nucleus accumbens of Lewis rats. J Pharmacol Exp Ther 1994;269:963-969.
92. Wilson JM, Nobrega JN, Carroll ME, Niznik HB, Shannak K, Lac ST, et al. Heterogeneous subregional binding patterns of 3H-WIN 35, 428 and 3H-GBR 12, 935 are differentially regulated by chronic cocaine self-administration. J Neurosci 1994;14:2966-2979.
93. Boulay D, Duterte-Boucher D, Leroux-Nicollet I, Naudon L, Costentin J. Locomotor sensitization and decrease in [3H]mazindol binding to the dopamine transporter in the nucleus accumbens are delayed after chronic treatments by GBR12783 or cocaine. J Pharmacol Exp Ther 1996;278: 330-337.
94. Pilotte NS, Sharpe LG, Rountree SD, Kuhar MJ. Cocaine withdrawal reduces dopamine transporter binding in the shell of the nucleus accumbens. Synapse 1996;22:87-92.
95. Alburges ME, Narang N, Wamsley JK. Alterations in the dopaminergic receptor system after chronic administration of cocaine. Synapse 1993;14:314-323.
96. Little KY, Kirkman JA, Carroll FI, Clark TB, Duncan GE. Cocaine use increases [3H]WIN 35428 binding sites in human striatum. Brain Res 1993;628:17-25.
97. Staley JK, Hearn WL, Ruttenber AJ, Wetli CV, Mash DC. High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J Pharmacol Exp Ther 1994;271:1678-1685.
98. Hitri A, Little KY, Ellinwood EH Jr. Effect of cocaine on dopamine transporter receptors depends on routes of chronic cocaine administration. Neuropsychopharmacology 1996;14:205-210.
99. Little KY, McLaughlin DP, Zhang L, McFinton PR, Dalack GW, Cook EH Jr, et al. Brain dopamine transporter messenger RNA and binding sites in cocaine users: a postmortem study. Arch Gen Psychiatry 1998;55:793-799
100. Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, et al. Elevated striatal dopamine transporters during acute cocaine bstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry 1998;155: 832-834.
101. Little KY, Zhang L, Desmond T, Frey KA, Dalack GW, Cassin BJ. Striatal dopaminergic abnormalities in human cocaine users. Am J Psychiatry 1999;156:238-245.
102. Allard P, Eriksson K, Ross SB, Marcusson JO. Unaltered [3H]GBR-12935 binding after chronic treatment with dopamine active drugs. Psychopharmacology (Berl) 1990; 102:291-294.
103. Kula NS, Baldessarini RJ. Lack of increase in dopamine transporter binding or function in rat brain tissue after treatment with blockers of neuronal uptake of dopamine. Neuropharmacology 1991;30:89-92.
104. Benmansour S, Tejani-Butt SM, Hauptmann M, Brunswick DJ. Lack of effect of high-dose cocaine on monoamine uptake sites in rat brain measured by quantitative autoradiography. Psychopharmacology (Berl) 1992;106: 459-462.
105. Cass WA, Gerhardt GA, Gillespie K, Curella P, Mayfield RD, Zahniser NR. Reduced clearance of exogenous dopamine in rat nucleus accumbens, but not in dorsal striatum, following cocaine challenge in rats withdrawn from repeated cocaine administration. J Neurochem 1993;61:273-283.
106. Wilson JM, Nobrega JN, Corrigall WA, Coen KM, Shannak K, Kish SJ. Amygdala dopamine levels are markedly elevated after self-but not passive-administration of cocaine. Brain Res 1994;668:39-45.
107. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 1996;40:428-439.
108. Kunko PM, Loeloff RJ, Izenwasser S. Chronic administration of the selective dopamine uptake inhibitor GBR 12, 909, but not cocaine, produces marked decreases in dopamine transporter density. Naunyn Schmiedebergs Arch Pharmacol 1997;356:562-569.
109. Letchworth SR, Sexton T, Childers SR, Vrana KE, Vaughan RA, Davies HM, et al. Regulation of rat dopamine transporter mRNA and protein by chronic cocaine administration. J Neurochem 1999;73:1982-1989.
110. Kimmel HL, Carroll FI, Kuhar MJ. Withdrawal from repeated cocaine alters dopamine transporter protein turnover in the rat striatum. J Pharmacol Exp Ther 2003;304:15-21.
111. Chen N, Reith ME. Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. J Neurochem 2007;101:377-388.
112. Shippenberg TS, Heidbreder C, Lefevour A. Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics. Eur J Pharmacol 1996;299:33-39.
113. Steketee JD. Cortical mechanisms of cocaine sensitization. Crit Rev Neurobiol 2005;17:69-86.
114. Zahniser NR, Peris J, Dwoskin LP, Curella P, Yasuda RP, O'Keefe L, et al. Sensitization to cocaine in the nigrostriatal dopamine system. NIDA Res Monogr 1988;88:55-77.
115. Ujike H, Tsuchida K, Akiyama K, Otsuki S. Supersensitivity of sigma receptors after repeated administration of cocaine. Life Sci 1992;51:PL31-PL36.
116. Itzhak Y, Stein I. Sensitization to the toxic effects of cocaine in mice is associated with the regulation of N-methyl-D-aspartate receptors in the cortex. J Pharmacol Exp Ther 1992;262:464-470.
117. Kim DS, Froelick GJ, Palmiter RD. Dopamine-dependent desensitization of dopaminergic signaling in the developing mouse striatum. J Neurosci 2002;22:9841-9849.
118. Fang Y, Ronnekleiv OK. Cocaine upregulates the dopamine transporter in fetal rhesus monkey brain. J Neurosci 1999;19:8966-8978.
119. Daws LC, Callaghan PD, Morón JA, Kahlig KM, Shippenberg TS, Javitch JA, et al. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun 2002;290: 1545-1550.
120. Mash DC, Pablo J, Ouyang Q, Hearn WL, Izenwasser S. Dopamine transport function is elevated in cocaine users. J Neurochem 2002;81:292-300.
121. Kahlig KM, Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol 2003;479: 153-158.
122. Cerruti C, Pilotte NS, Uhl G, Kuhar MJ. Reduction in dopamine transporter mRNA after cessation of repeated cocaine administration. Brain Res Mol Brain Res 1994;22:132-138.
123. Leslie CA, Robertson MW, Jung AB, Liebermann J, Bennett JP Jr. Effects of prenatal cocaine exposure upon postnatal development of neostriatal dopaminergic function. Synapse 1994;17:210-215.
124. Stadlin A, Choi HL, Tsang D. Postnatal changes in [3H]mazindol-labelled dopamine uptake sites in the rat striatum following prenatal cocaine exposure. Brain Res 1994;637:345-348.
125. Collins LM, Meyer JS. Prenatal cocaine alters dopamine transporter binding in postnatal day 10 rat striatum. Synapse 1996;23:335-343.
126. Tella SR, Ladenheim B, Andrews AM, Goldberg SR, Cadet JL. Differential reinforcing effects of cocaine and GBR-12909: biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system. J Neurosci 1996;16:7416-7427.
127. Little KY, Elmer LW, Zhong H, Scheys JO, Zhang L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol Pharmacol 2002;61:436-445.
128. Zahniser NR, Doolen S. Chronic and acute regulation of Na?/Cl-dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol Ther 2001;92:21-55.
129. Cowell RM, Kantor L, Hewlett GH, Frey KA, Gnegy ME. Dopamine transporter antagonists block phorbol esterinduced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur J Pharmacol 2000;389:59-65.
130. Torres GE, Caron MG. Approaches to identify monoamine transporter interacting proteins. J Neurosci Methods 2005;143:63-68.
131. Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, et al. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domaincontaining protein PICK1. Neuron 2001;30:121-134.
132. Carneiro AM, Ingram SL, Beaulieu JM, Sweeney A, Amara SG, Thomas SM, et al. The multiple LIM domaincontaining adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter. J Neurosci 2002;22:7045-7054.
133. Lee KH, Kim MY, Kim DH, Lee YS. Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter. Neurochem Res 2004;29:1405-1409.
134. Dickinson SD, Sabeti J, Larson GA, Giardina K, Rubinstein M, Kelly MA, et al. Dopamine D2 receptordeficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem 1999;72:148-156.
135. Lee FJ, Pei L, Moszczynska A, Vukusic B, Fletcher PJ, Liu F. Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J 2007;26:2127-2136.
136. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003;4:13-25.
137. Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995;56:993-998.
138. Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL, et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 1998;63:1767-1776.
139. Madras BK, Fahey MA, Goulet M, Lin Z, Bendor J, Goodrich C, et al. Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. J Pharmacol Exp Ther 2006;319:570-585.
140. Rodriguiz RM, Chu R, Caron MG, Wetsel WC. Aberrant responses in social interaction of dopamine transporter knockout mice. Behav Brain Res 2004;148:185-198.
141. Tillerson JL, Caudle WM, Parent JM, Gong C, Schallert T, Miller GW. Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor. Behav Brain Res 2006;172:97-105.
142. Kavelaars A, Cobelens PM, Teunis MA, Heijnen CJ. Changes in innate and acquired immune responses in mice with targeted deletion of the dopamine transporter gene. J Neuroimmunol 2005;161:162-168.
143. Wang GJ, Volkow ND, Fowler JS, Fischman M, Foltin R, Abumrad NN, et al. Cocaine abusers do not show loss of dopamine transporters with age. Life Sci 1997;61:1059-1065.
144. Carroll FI, Howell LL, Kuhar MJ. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 1999;42:2721-2736.
145. Mead AN, Rocha BA, Donovan DM, Katz JL. Intravenous cocaine induced-activity and behavioural sensitization in norepinephrine-, but not dopamine-transporter knockout mice. Eur J Neurosci 2002;16:514-520.
146. Howell LL, Wilcox KM. The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther 2001;298: 1-6.
147. Ginsburg BC, Kimmel HL, Carroll FI, Goodman MM, Howell LL. Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys. Pharmacol Biochem Behav 2005;80:481-491.
148. Lile JA, Morgan D, Birmingham AM, Davies HM, Nader MA. Effects of the dopamine reuptake inhibitor PTT on reinstatement and on food-and cocaine-maintained responding in rhesus monkeys. Psychopharmacology (Berl) 2004;174:246-253.
149. Gulley JM, Hoover BR, Larson GA, Zahniser NR. Individual differences in cocaine-induced locomotor activity in rats: behavioral characteristics, cocaine pharmacokinetics, and the dopamine transporter. Neuropsychopharmacology 2003;28:2089-2101.
150. Briegleb SK, Gulley JM, Hoover BR, Zahniser NR. Individual differences in cocaine-and amphetamineinduced activation of male Sprague-Dawley rats: contribution of the dopamine transporter. Neuropsychopharmacology 2004;29:2168-2179.
151. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997;386:827-830.
152. Venton BJ, Seipel AT, Phillips PE, Wetsel WC, Gitler D, Greengard P, et al. Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci 2006;26:3206-3209.